Author

D. Lange

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:metagenomics· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Keshavarzian· 1 shared A. Lex· 1 shared B. K. Lohman· 1 shared C. Stubben· 1 shared D. A. Hall· 1 shared D. Grossman· 1 shared D. J. Hakim· 1 shared F. Vand-Rajabpour· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Keshavarzian

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrated multi-cohort analysis of the Parkinson's disease gut metagenome

J. C. Boktor, G. Sharon, L. A. Verhagen Metman, D. A. Hall, P. A. Engen, Z. Zreloff, D. J. Hakim, J. W. Bostick, J. Ousey, D. Lange, G. Humphrey, G. Ackermann, M. Carlin, R. Knight, A. Keshavarzian, S. K. Mazmanian

This study analyzes the gut microbiome in Parkinson's disease across multiple cohorts, identifying consistent taxonomic and functional changes associated with the disease.

bioRxiv · Jul 20, 2022Microbiology

Bidirectional interconversion between mutually exclusive tumorigenic and drug-tolerant melanoma cell phenotypes

Y. Zhang, R. L. Belote, M. A. Urquijo, M. M. Hansen, M. Hejna, T. E. Moustafa, T. Liu, D. Lange, F. Vand-Rajabpour, M. Chang, B. K. Lohman, C. Stubben, X. Zhang, L. S. Weinberger, M. W. VanBrocklin, , R. L. Judson-Torres

This study identifies bidirectional interconversion between tumorigenic and drug-tolerant melanoma cell states through BRN2 expression, revealing distinct molecular programs and therapeutic implications.

bioRxiv · Aug 26, 2020 · PreprintCancer Biology